DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Nuclear Medicine Radioisotopes Market - Analysis and Forecasts (2015-2020)" report to their offering.
The global market for Radioisotopes is estimated to be valued as $9.61 billion in 2015 and is expected to reach $17.28 billion by the end of 2020. During this period of forecast the market is expected to grow at a CAGR of 12.45%.
Major driving factors for the growth of the market are increasing demand of SPECT analysis in radiopharmaceuticals, development of better instruments, newer computer based procedures for image analysis and display, new 99mTc labeled agents for visualizing biologically significant events, increasing demand of PET analysis in radiopharmaceuticals, increasing use in clinical applications to study psychiatric disorders. Integration of X-ray tomography (CT) into SPECT has recently emerged as a brilliant diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market.
SPECT radioisotopes chemical form of thallous chloride has been the principle tracer used in myocardial perfusion imaging. Technetium-99m is the major radioisotope used in SPECT. Generally technetium is produced in technetium generators.Tl-201 is used in myocardial perfusion studies, In-111 is used in prostate cancer, and Ga-67 is used in lymphoma diagnosis and treatment.
- Agfa-Gevaert N.V.
- Cardiarc Ltd
- Digirad Corporation
- Gamma Medica Inc
- Ge Healthcare
- Hologic Inc.
- Medx Inc
- Naviscan Inc
- Positron Corporation
- Segami Corporation
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS DROC
8. Competitive Landscape
9. Key Vendor Analysis
10. Analyst Outlook for Investment Opportunities
11. Future Outlook of the Market
For more information visit http://www.researchandmarkets.com/research/6ghv6r/global_nuclear